|Bid||9.12 x 200|
|Ask||16.98 x 200|
|Day's Range||12.36 - 12.64|
|52 Week Range||7.70 - 15.20|
|PE Ratio (TTM)||-13.70|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.77|
SAN DIEGO, May 25, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting a corporate overview ...
SAN DIEGO, May 24, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced today the completion of its previously announced underwritten public offering of 11,500,000 shares of its common stock. The offering included 1,500,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. All shares in the offering were sold by Halozyme at a public offering price of $12.50 per share.
Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Halozyme Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)